{"id":3680,"date":"2025-03-31T18:11:47","date_gmt":"2025-03-31T18:11:47","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/amiloride-hydrochloride-txt\/"},"modified":"2025-03-31T18:11:47","modified_gmt":"2025-03-31T18:11:47","slug":"amiloride-hydrochloride-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/amiloride-hydrochloride-txt\/","title":{"rendered":"Amiloride hydrochloride.txt"},"content":{"rendered":"

Amiloride hydrochloride<\/h1>\n

CLINICAL USE <\/H3><\/p>\n
  • Oedema\n
  • Potassium conservation with thiazide and\n

    loop diuretics
    \n

    DOSE IN NORMAL RENAL FUNCTION <\/H3>
    \n5\u201310 mg daily; maximum 20 mg daily
    \n

    PHARMACOKINETICS <\/H3>
    \n
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n302.1\n<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n30\u201340\n<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp :
    \n50\n<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :
    \n5\n<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :
    \n6\u201320\/100
    \n

    DOSE IN RENAL IMPAIRMENT <\/H3>
    \n

    GFR (mL\/MIN)<\/H4>
    \n
  • 20 to 50 &nbsp &nbsp : Use 50% of dose
    \n
  • 10 to 20 &nbsp &nbsp : Use 50% of dose
    \n
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nAvoid
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
    \n
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
    \nNot applicable. Avoid<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nNot applicable. Avoid
    \n
  • HDF\/high flux &nbsp :
    \nNot applicable. Avoid
    \n
  • CAV\/VVHD &nbsp &nbsp &nbsp:
    \nUnknown dialysability. Dose as in
    \nGFR 10 to 20 mL\/min
    \n

    IMPORTANT DRUG INTERACTIONS <\/H3>
    \nPotentially hazardous interactions with other drugs<\/p>\n
  • ACE inhibitor and angiotensin-\n

    II antagonists: increased risk of
    \nhyperkalaemia and hypotension
    \nAntibacterials: avoid concomitant use with <\/p>\n

    lymecycline<\/p>\n

  • Antidepressants: increased risk of postural\n

    hypotension with tricyclics; enhanced
    \nhypotensive effect with MAOIs
    \nAntihypertensives: enhanced hypotensive <\/p>\n

    effect<\/p>\n

  • Ciclosporin: increased risk of\n

    hyperkalaemia and nephrotoxicity
    \nLithium excretion reduced<\/p>\n

  • NSAIDS: increased risk of hyperkalaemia;\n

    increased risk of <\/p>\n

  • nephrotoxicity;
    \nantagonism of diuretic effect<\/p>\n
  • Potassium salts: increased risk of\n

    hyperkalaemia<\/p>\n

  • Tacrolimus: increased risk of\n

    hyperkalaemia
    \n

    ADMINISTRATION <\/H3>
    \n

    Reconstition<\/H4>
    \n\u2013
    \n

    Route <\/H4>
    \nOral<\/p>\n

    Rate of Administration <\/H4>
    \n\u2013
    \n

    Comments<\/H4>
    \n\u2013
    \n

    OTHER INFORMATION <\/H4><\/p>\n
  • Monitor for hyperkalaemia\n
  • Greatly increased risk of hyperkalaemia in\n

    patients with a GFR<30 mL\/min, especially
    \nin diabetics<\/p>\n

  • Increased risk of hyperchloraemic\n

    metabolic acidosis in patients with
    \nreduced GFR<\/p>\n

  • Bioavailability is 50% and can be reduced\n

    by administering with food<\/p>\n

  • Reduced natriuretic effect once the\n

    GFR<50 mL\/min<\/p>\n

  • Diuretic effect starts 2 hours after\n

    administration, peaks after 6\u201310 hours
    \nand can last up to 24 hours<\/p>\n","protected":false},"excerpt":{"rendered":"

    Amiloride hydrochloride CLINICAL USE Oedema Potassium conservation with thiazide and<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3680","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3680"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3680\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3680"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3680"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}